Jun 02, 2020 EBMT to track long-term outcome data for Yescarta®, a CAR T therapy for adults living with two types of aggressive non-Hodgkin lymphoma
Mar 01, 2019 EBMT receives a regulatory qualification from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies.